JP2011526792A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011526792A5 JP2011526792A5 JP2011516886A JP2011516886A JP2011526792A5 JP 2011526792 A5 JP2011526792 A5 JP 2011526792A5 JP 2011516886 A JP2011516886 A JP 2011516886A JP 2011516886 A JP2011516886 A JP 2011516886A JP 2011526792 A5 JP2011526792 A5 JP 2011526792A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- domain
- multispecific fusion
- antagonist
- linker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000037865 fusion proteins Human genes 0.000 claims description 34
- 108020001507 fusion proteins Proteins 0.000 claims description 34
- 239000005557 antagonist Substances 0.000 claims description 20
- 230000027455 binding Effects 0.000 claims description 12
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 102000040430 polynucleotide Human genes 0.000 claims description 5
- 108091033319 polynucleotide Proteins 0.000 claims description 5
- 239000002157 polynucleotide Substances 0.000 claims description 5
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 4
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 108010028006 B-Cell Activating Factor Proteins 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 201000009273 Endometriosis Diseases 0.000 claims description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 2
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 claims description 2
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 claims description 2
- 101000801228 Homo sapiens Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims description 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims description 2
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims description 2
- 102000003814 Interleukin-10 Human genes 0.000 claims description 2
- 108090000174 Interleukin-10 Proteins 0.000 claims description 2
- 102100033461 Interleukin-17A Human genes 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 229940124044 RANKL antagonist Drugs 0.000 claims description 2
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 claims description 2
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 208000019069 chronic childhood arthritis Diseases 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- FOCAHLGSDWHSAH-UHFFFAOYSA-N difluoromethanethione Chemical compound FC(F)=S FOCAHLGSDWHSAH-UHFFFAOYSA-N 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000003463 hyperproliferative effect Effects 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 230000000737 periodic effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 7
- 230000009870 specific binding Effects 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13410008P | 2008-07-02 | 2008-07-02 | |
| US13409608P | 2008-07-02 | 2008-07-02 | |
| US13409808P | 2008-07-02 | 2008-07-02 | |
| US13409508P | 2008-07-02 | 2008-07-02 | |
| US13410108P | 2008-07-02 | 2008-07-02 | |
| US13409908P | 2008-07-02 | 2008-07-02 | |
| US13409708P | 2008-07-02 | 2008-07-02 | |
| US61/134,098 | 2008-07-02 | ||
| US61/134,096 | 2008-07-02 | ||
| US61/134,095 | 2008-07-02 | ||
| US61/134,097 | 2008-07-02 | ||
| US61/134,101 | 2008-07-02 | ||
| US61/134,100 | 2008-07-02 | ||
| US61/134,099 | 2008-07-02 | ||
| US18009709P | 2009-05-20 | 2009-05-20 | |
| US61/180,097 | 2009-05-20 | ||
| PCT/US2009/049603 WO2010003108A2 (en) | 2008-07-02 | 2009-07-02 | TNF-α ANTAGONIST MULTI-TARGET BINDING PROTEINS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011526792A JP2011526792A (ja) | 2011-10-20 |
| JP2011526792A5 true JP2011526792A5 (enExample) | 2012-08-16 |
Family
ID=41051379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011516886A Pending JP2011526792A (ja) | 2008-07-02 | 2009-07-02 | ＴＮＦ−αアンタゴニスト多重標的結合性タンパク質 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20110152173A1 (enExample) |
| EP (1) | EP2310410A2 (enExample) |
| JP (1) | JP2011526792A (enExample) |
| KR (1) | KR20110044991A (enExample) |
| CN (1) | CN102171247A (enExample) |
| AU (1) | AU2009266863A1 (enExample) |
| BR (1) | BRPI0914005A2 (enExample) |
| CA (1) | CA2729749A1 (enExample) |
| EA (1) | EA201170028A1 (enExample) |
| IL (1) | IL210264A0 (enExample) |
| MX (1) | MX2011000041A (enExample) |
| NZ (1) | NZ590668A (enExample) |
| WO (1) | WO2010003108A2 (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2248899T3 (pl) | 2003-03-19 | 2015-10-30 | Biogen Ma Inc | Białko wiążące receptor nogo |
| KR101239542B1 (ko) | 2004-06-24 | 2013-03-07 | 바이오겐 아이덱 엠에이 인코포레이티드 | 탈수초화를 수반하는 병의 치료 |
| CA2902070A1 (en) | 2005-07-08 | 2007-01-18 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
| ES2378407T3 (es) | 2006-09-01 | 2012-04-12 | Therapeutic Human Polyclonals, Inc. | Aumento de la expresión de inmunoglobulina humana o humanizada en animales transgénicos no humanos |
| EA019512B1 (ru) * | 2008-07-02 | 2014-04-30 | Эмерджент Продакт Дивелопмент Сиэтл, Ллс | Il-6-опосредованная иммунотерапия |
| JP2011527572A (ja) * | 2008-07-09 | 2011-11-04 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Ｌｉｎｇｏ抗体または断片を含む組成物 |
| WO2010042904A2 (en) * | 2008-10-10 | 2010-04-15 | Trubion Pharmaceuticals, Inc. | Tcr complex immunotherapeutics |
| EP2516467A2 (en) * | 2009-12-23 | 2012-10-31 | Emergent Product Development Seattle, LLC | Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof |
| KR101004362B1 (ko) * | 2010-03-19 | 2010-12-28 | 가톨릭대학교 산학협력단 | 자가 면역 질환 예방 및 치료용 ＴＮＦ－α와 ＴＷＥＡＫ 이중 길항제 |
| KR101004363B1 (ko) | 2010-03-19 | 2010-12-28 | 가톨릭대학교 산학협력단 | 자가 면역 질환 예방 및 치료용 ＴＮＦ－α와 ＩＬ－２１ 이중 길항제 |
| CN102443063B (zh) * | 2010-09-30 | 2013-10-23 | 成都康弘生物科技有限公司 | 抗TNFα的人源化Fab和人源化抗体及其用途 |
| BR112013020086B1 (pt) * | 2011-02-08 | 2020-12-08 | Medimmune, Llc | Anticorpo isolado ou seu fragmento de ligação a antígeno, composição compreendendo o anticorpo ou fragmento de ligação a antígeno, kit, uso de uma quantidade eficaz de um anticorpo ou seu fragmento de ligação a antígeno e método para inibir a formação da oligômeros de alfatoxina |
| WO2013065343A1 (ja) * | 2011-10-31 | 2013-05-10 | 株式会社 島津製作所 | 非ペプチドヒンジ部含有フレキシブル抗体様分子 |
| WO2013075027A2 (en) * | 2011-11-17 | 2013-05-23 | Emergent Product Development Seattle, Llc | Anti-sil6xr complex binding domains and methods of use |
| WO2013086636A1 (en) * | 2011-12-15 | 2013-06-20 | The Royal Institution For The Advancement Of Learning/Mcgill University | Soluble igf receptor fc fusion proteins and uses thereof |
| WO2013116682A1 (en) | 2012-02-02 | 2013-08-08 | Ensemble Therapeutics Corporation | Macrocyclic compounds for modulating il-17 |
| CA2868404A1 (en) | 2012-04-05 | 2013-10-10 | F. Hoffmann-La Roche Ag | Bispecific antibodies against human tweak and human il17 and uses thereof |
| KR20150004856A (ko) | 2012-04-20 | 2015-01-13 | 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 | Cd3 결합 폴리펩타이드 |
| KR102023401B1 (ko) | 2012-05-10 | 2019-11-04 | 바이오아트라, 엘엘씨 | 다중-특이적 모노클로날 항체 |
| MX381731B (es) | 2012-05-14 | 2025-03-13 | Biogen Ma Inc | Antagonistas de proteina que interactua con el receptor nogo 2 que contiene repeticion rica en leucina y dominio de inmunoglobulina (lingo-2) para el tratamiento de afecciones que involucran neuronas motoras. |
| CN103060274B (zh) * | 2012-12-28 | 2013-12-11 | 首都医科大学 | Rankl-tnf样区鼠源性单克隆抗体及其制备方法与应用 |
| US20140219913A1 (en) * | 2012-12-28 | 2014-08-07 | Abbvie, Inc. | Dual Specific Binding Proteins Having a Receptor Sequence |
| NL2011406C2 (en) | 2013-09-06 | 2015-03-10 | Bionovion Holding B V | Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides. |
| CA2924520C (en) | 2013-11-01 | 2023-09-26 | Ibc Pharmaceuticals, Inc. | Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease |
| JP2018504400A (ja) | 2015-01-08 | 2018-02-15 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用 |
| NL2014108B1 (en) * | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
| KR20250008141A (ko) | 2015-08-07 | 2025-01-14 | 이미지냅 인코포레이티드 | 분자를 표적화하기 위한 항원 결합 구조체 |
| KR102784293B1 (ko) | 2015-09-21 | 2025-03-20 | 압테보 리서치 앤드 디벨롭먼트 엘엘씨 | Cd3 결합 폴리펩타이드 |
| CN113862300A (zh) * | 2015-10-29 | 2021-12-31 | 豪夫迈·罗氏有限公司 | 具有共同轻链的转基因兔 |
| EP3293293A1 (en) * | 2016-09-08 | 2018-03-14 | Italfarmaco SpA | Hc-cdr3-only libraries with reduced combinatorial redundancy and optimized loop length distribution |
| WO2018147960A1 (en) | 2017-02-08 | 2018-08-16 | Imaginab, Inc. | Extension sequences for diabodies |
| PE20242042A1 (es) | 2017-06-02 | 2024-10-10 | Pfizer | Anticuerpos especificos para flt3 y sus usos |
| JP6895165B2 (ja) * | 2017-06-06 | 2021-06-30 | 知和 松浦 | α１−アンチキモトリプシンを含むバイオマーカー |
| IL272103B2 (en) | 2017-07-20 | 2024-10-01 | Aptevo Res & Development Llc | Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods of treating cancer |
| CN112513081A (zh) | 2018-06-14 | 2021-03-16 | 生物蛋白有限公司 | 多重特异性抗体构建体 |
| TWI809130B (zh) * | 2018-06-22 | 2023-07-21 | 美商凱特製藥公司 | 嵌合跨膜蛋白及其用途 |
| US11155606B2 (en) | 2018-07-24 | 2021-10-26 | Medimmune, Llc | Antibody directed against S. aureus clumping factor a (ClfA) |
| BR112021006622A2 (pt) | 2018-10-09 | 2021-07-20 | Medimmune, Llc | combinações de anticorpos anti-staphylococcus aureus |
| KR102404684B1 (ko) * | 2019-01-15 | 2022-06-07 | 서울대학교산학협력단 | 인슐린 유사 성장인자 2 억제제를 포함하는 만성 폐질환의 예방 또는 치료용 조성물 |
| MX2022001882A (es) | 2019-08-12 | 2022-05-30 | Aptevo Res & Development Llc | Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40. |
| WO2021146328A1 (en) | 2020-01-13 | 2021-07-22 | Aptevo Research And Development Llc | Formulations for protein therapeutics |
| AU2021377176A1 (en) * | 2020-11-11 | 2023-06-22 | Hq Han | Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof |
| CN112451670B (zh) * | 2020-11-25 | 2024-01-02 | 沣潮医药科技（上海）有限公司 | 异位内膜治疗的组合物和预后检测试剂盒 |
| EP4255574A1 (en) | 2020-12-01 | 2023-10-11 | Aptevo Research and Development LLC | Heterodimeric psma and cd3-binding bispecific antibodies |
| CN115073607A (zh) * | 2021-03-12 | 2022-09-20 | 上海康岱生物医药技术股份有限公司 | Tnfr2与baff受体的融合蛋白 |
| JP2024519964A (ja) | 2021-05-21 | 2024-05-21 | アプティーボ リサーチ アンド デベロップメント エルエルシー | タンパク質治療薬のための投薬レジメン |
| WO2023164898A1 (zh) * | 2022-03-03 | 2023-09-07 | 上海赛金生物医药有限公司 | 一种重组融合蛋白的制剂 |
| WO2023178306A2 (en) * | 2022-03-18 | 2023-09-21 | Fab Biopharma, Inc. | Compositions and methods for treatment of sjögren's syndrome and/or systemic lupus erythematosus |
| CN120584137A (zh) | 2023-01-06 | 2025-09-02 | 阿帕特夫研究和发展有限公司 | 双特异性pd-l1和cd40结合分子以及其用途 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0307434B2 (en) * | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5714585A (en) * | 1987-10-26 | 1998-02-03 | Sterling Winthrop, Inc. | Antibodies that are immunoreactive with interleukin-7 |
| DE69322289T2 (de) * | 1992-12-29 | 1999-05-20 | Genentech, Inc., South San Francisco, Calif. | Behandlung von entzündlichen darmerkrankungen mit interferon-gamma-inhibitoren |
| US20050147609A1 (en) * | 1998-05-15 | 2005-07-07 | Genentech, Inc. | Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis |
| EE200100372A (et) * | 1999-01-15 | 2002-10-15 | Biogen, Incorporated | TWEAK-valgu ja TWEAK-valgu retseptori antagonistid ja nende kasutamine immuunhaiguste raviks |
| US7220840B2 (en) * | 2000-06-16 | 2007-05-22 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator protein |
| CA2446734A1 (en) * | 2001-05-24 | 2002-11-28 | Human Genome Sciences, Inc. | Antibodies against tumor necrosis factor delta (april) |
| US20060073141A1 (en) * | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| DE10148217C1 (de) * | 2001-09-28 | 2003-04-24 | Bosch Gmbh Robert | Verfahren, Computerprogramm und Steuer- und/oder Regelgerät zum Betreiben einer Brennkraftmaschine, sowie Brennkraftmaschine |
| JP2006500905A (ja) * | 2002-02-13 | 2006-01-12 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | ヒト化ｇｍ−ｃｓｆ抗体 |
| US20050043516A1 (en) * | 2002-07-25 | 2005-02-24 | Genentech, Inc. | TACI antibodies and uses thereof |
| US8921528B2 (en) * | 2004-06-01 | 2014-12-30 | Domantis Limited | Bispecific fusion antibodies with enhanced serum half-life |
| WO2006043972A1 (en) * | 2004-10-12 | 2006-04-27 | Amprotein Corporation | Chimeric protein |
| JP2008523083A (ja) * | 2004-12-08 | 2008-07-03 | イムノメディクス， インコーポレイテッド | 炎症性疾患および免疫調節不全疾患、感染性疾患、病的血管新生およびがんの免疫療法および検出のための方法および組成物 |
| US7939490B2 (en) * | 2004-12-13 | 2011-05-10 | University Of Maryland, Baltimore | TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death |
| AU2006230099B2 (en) * | 2005-03-25 | 2012-04-19 | Gitr, Inc. | GITR binding molecules and uses therefor |
| NZ564027A (en) * | 2005-05-18 | 2011-06-30 | Morphosys Ag | Anti-GM-CSF antibodies and uses therefor |
| WO2006130429A2 (en) * | 2005-05-27 | 2006-12-07 | Biogen Idec Ma Inc. | Treatment of cancer |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| JP5364870B2 (ja) * | 2005-08-19 | 2013-12-11 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリン及びその使用 |
| CN103232540A (zh) * | 2006-02-01 | 2013-08-07 | 赛法隆澳大利亚控股有限公司 | 结构域抗体构建体 |
| CN105837690A (zh) * | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| KR20110044992A (ko) * | 2008-07-02 | 2011-05-03 | 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 | ＴＧＦ-β 길항제 다중-표적 결합 단백질 |
| EA019512B1 (ru) * | 2008-07-02 | 2014-04-30 | Эмерджент Продакт Дивелопмент Сиэтл, Ллс | Il-6-опосредованная иммунотерапия |
| US20110158995A1 (en) * | 2008-07-28 | 2011-06-30 | Renault S.A.S | Multi-Specific Binding Proteins Targeting B Cell Disorders |
| EP3281955A1 (en) * | 2008-10-02 | 2018-02-14 | Aptevo Research and Development LLC | Cd86 antagonist multi-target binding proteins |
| WO2010042904A2 (en) * | 2008-10-10 | 2010-04-15 | Trubion Pharmaceuticals, Inc. | Tcr complex immunotherapeutics |
-
2009
- 2009-07-02 CN CN2009801338489A patent/CN102171247A/zh active Pending
- 2009-07-02 EP EP09774557A patent/EP2310410A2/en not_active Withdrawn
- 2009-07-02 NZ NZ590668A patent/NZ590668A/xx not_active IP Right Cessation
- 2009-07-02 AU AU2009266863A patent/AU2009266863A1/en not_active Abandoned
- 2009-07-02 CA CA2729749A patent/CA2729749A1/en not_active Abandoned
- 2009-07-02 WO PCT/US2009/049603 patent/WO2010003108A2/en not_active Ceased
- 2009-07-02 US US13/001,087 patent/US20110152173A1/en not_active Abandoned
- 2009-07-02 KR KR1020117002700A patent/KR20110044991A/ko not_active Withdrawn
- 2009-07-02 EA EA201170028A patent/EA201170028A1/ru unknown
- 2009-07-02 MX MX2011000041A patent/MX2011000041A/es not_active Application Discontinuation
- 2009-07-02 BR BRPI0914005A patent/BRPI0914005A2/pt not_active IP Right Cessation
- 2009-07-02 JP JP2011516886A patent/JP2011526792A/ja active Pending
-
2010
- 2010-12-26 IL IL210264A patent/IL210264A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6820242B2 (ja) | 抗体のＦｃ領域改変体 | |
| Silacci et al. | Linker length matters, fynomer-Fc fusion with an optimized linker displaying picomolar IL-17A inhibition potency | |
| JP2023525032A (ja) | Ｔ細胞阻害タンパク質を伴うおよび伴わない、ａｐｒｉｌおよびｂａｆｆ阻害免疫調節タンパク質、ならびにその使用方法 | |
| JP2015524799A5 (enExample) | ||
| JP2018512145A5 (enExample) | ||
| JP2011526794A5 (enExample) | ||
| JP6943764B2 (ja) | Ｉｌ−１７ａ結合ポリペプチド | |
| JP2014518883A5 (enExample) | ||
| RU2015142999A (ru) | Слитые белки, содержащие связывающие части pdgf и vegf, и способы их применения | |
| WO2012172521A1 (en) | Soluble proteins for use as therapeutics | |
| PT2697257T (pt) | Proteínas de fusão fc compreendendo novos ligantes ou arranjos | |
| RS61493B1 (sr) | Konstrukti multispecifičnih antitela | |
| JP7097293B2 (ja) | ヒトＦｃ受容体に結合する融合タンパク質 | |
| JP2013529070A5 (enExample) | ||
| AU2009266863A1 (en) | TNF-alpha antagonist multi-target being proteins | |
| EP3986920B1 (en) | Tnfr2 agonists with improved stability | |
| JP2022528324A (ja) | 抗ｉｌ１３ｒ抗体またはその結合フラグメントを用いた治療 | |
| WO2011079308A2 (en) | Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof | |
| BR112020025030A2 (pt) | anticorpos que compreendem um polipeptídeo inserido na região de framework 3 | |
| WO2019096026A1 (zh) | 抗il-17抗体/tnfr ecd融合蛋白及其用途 | |
| RU2019123112A (ru) | Анти-il-5 антитела | |
| JP2023552829A (ja) | 免疫細胞機能を調節するための変異インターロイキン－１０ポリペプチドの抗原結合分子との融合物 | |
| JP2014124186A (ja) | 多価抗体フラグメントおよびその三量体化複合体 | |
| CN106536567A (zh) | 新型多肽 | |
| WO2023079278A1 (en) | Novel proteins |